natgillin/translations-raw huggingface dataset:
A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R1 represents a group represented by the formula -NR11aR11b,wherein R11a and R11b represent the same meaning as recited in Claim 1. 
Spoj prema zahtjevu 1, njegova sol ili hidrat navedenog, naznačen time da R' predstavlja skupinu prikazanu sa formulom -NR/'*R'", pri čemu R''*i R!" imaju isto značenje kako je navedeno u zahtjevu 1.
or a pharmaceutically acceptable salt, hydrate, solvate or crystalline form of any of the foregoing. 
OR O F ili farmaceutski prihvatljive soli bilo kojeg od navedenih spojeva.
Another embodiment of the present invention provides use of compound A for preparation of a low dose pharmaceutical composition for the treatment of IBD in a mammal. 
Niskodozni farmaceutski preparat, za upotrebu u liječenju inflamatorne crijevne bolesti prema bilo kom od prethodnih patentnih zahtjeva je za ne-parenteralnu primjenu.
The inflow end can be brought into engagement with the shut-off valve of the container, for example by closing the lid, as a result of which the line is moved downwards and is able to open the spring-loaded shut-off valve of the container. 
Ulazni kraj se može dovesti u doticaj s ventilom za zatvaranje na spremniku, na primjer zatvaranjem poklopca, a kao rezultat toga cijev se pomiče prema dolje i moguće je otvoriti ventil na oprugu za zatvaranje spremnika.
As illustrated in the chart above, only compound of formula I demonstrate favorable characteristics in all of the categories tested. 
Kao što je ilustrirano u tabeli u prethodnom tekstu, samo spoj formule I pokazuje povoljne karakteristike u svim testiranim kategorijama.
As discussed hereinabove, it is desirable to adjust the effective rate of the spring 24 in order to accommodate differing tensile strengths of wireline used in conjunction with the jar 10; and differing toolstring masses. 
Kao što je to već ranije navedeno, poželjno je podesiti efektivnu jačinu opruge 24 u cilju prilagođavanja različitim otporima žičane veze, korištene zajedno s udaračem 10, 1 različitim masama.
The compound for use according to embodiment 11, wherein the disease is psoriasis. 
Spoj za upotrebu prema zahtjevu 18, pri čemu je bolest psorijaza.
Safety link according to claim 3 or 4, characterized in that the two control modules that are located on the same side (ship or shore) are switchable to opposite modes, i.e. 
Sigurnosna veza prema zahtjevu 3 ili 4, naznačena time da se dva upravljačka modula koji se nalaze na istoj strani mogu prebaciti na različite načine rada, tj.
n is an integer selected from the group consisting of: 1, 2, 3, 4, and 5; 
Spoj za uporabu prema zahtjevu 1 ili 2, naznačen time što je spoj odabran iz skupine koja se sastoji od:
Process according to claim 1, CHARACTERIZED in that the alkali in step (a) is chosen from the group consisting of sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide and their mixtures, and the weight ratio of alkali to crude or refined oil is approximately 0.15:1 and the weight ratio of water to crude or refined oil is between 0.5:1 and 2:1. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se alkalija u koraku (a) bira iz skupine koju čine natrijev hidroksid, kalijev hidroksid, litijev hidroksid, magnezijev hidroksid i njihove smjese, težinski omjer između alkalije 1 sirovog ili rafiniranog ulja je približno 0,15:1, a težinski omjer između vode 1 sirovog ili rafiniranog ulja je između 0,5:1 12:1.
hyperglycemia; or hyperinsulinemia; wherein the method comprises administering a therapeutically effective amount of the isolated antibody or fragment or the pharmaceutical composition to a patient in need thereof for a time sufficient to treat or prevent the inflammatory condition, the type II diabetes, hyperglycemia or insulin resistance. 
V) je povezana sa gastrointestinalnom ulceracijom, opciono infektivnim kolitisom, ishemijskim kolitisom, kolagenoznim ili limfocitnim kolitisom ili nekrotizirajućim enterokolitisom; ili vi) je autoimuna bolest, opciono reumatoidna b) dijabetes tipa II; c) hiperglikemija; ili d) hiperinsulinemija; pri čemu se postupak sastoji od administriranja terapeutski efikasne količine izoliranog antitijela ili fragmenta ili farmaceutske kompozicije pacijentu kome je to potrebno tokom vremena dovoljnog za liječenje ili prevenciju inflamatornog stanja, dijabetesa tipa II, hiperglikemije ili rezistentnosti na inzulin.
The method of claim 14 or claim 15, wherein the inducible promoter is a T7 promoter. The method of any one of the preceding claims, wherein the chromosome of the microbial host cell comprises a nucleic acid sequence coding for a bacteriophage RNA polymerase, optionally operably linked to a lac promoter, and is free of lysogenic bacteriophage nucleic acid sequences. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što kromosom bakterijske stanice domaćina sadrži nukleinskokiselinski slijed koji kodira RNA polimerazu iz bakteriofaga, operabilno spregnut s lac promotorom, te ne sadrži nukleinskokiselinske sljedove lizogenih bakteriofaga, gdje RNA polimeraza iz bakteriofaga može biti polimeraza T7.
Frozen or deep-frozen food products based on leavened dough, leavened puff pastry dough or puff pastry dough, having an upper and a lower surface, characterised in that at least said lower surface comprises a curved or corrugated shape, preferably the shape of an arch, or two or more arches which are tandemly arranged. 
HR P20180896 T1 Smrznute ili duboko smrznute slastice od tijesta, kroasani ili čokoladne rolice, koje imaju gornju i donju površinu, naznačene time, da barem navedena donja površina ima oblik višestrukih lukova koji su raspoređeni u paru.
solid acid or suitably acid-functionalised materials such as perfluorinated oxides and/or polymers; silicas and silicas doped with Al, Ti or Zr in different morphologies, heteropolyacids, acids adsorbed and/or covalently bonded to metal oxides; organic sulphonic and/or organic carboxylic acids immobilised on amorphous silica and/or meso- and microstructured silica; polyoxymetalates stabilised on silica and/or titania; Keggin structures containing niobium ions; niobium oxides; ionic liquids and/or carbon nanotubes functionalised with organic sulphonic acids and/or organic carboxylic acids. 
– čvrsta kiselina ili pogodni materijali funkcionalizirani u kiseline kao što su perfluorirani oksidi i/ili polimeri; silicijevi dioksidi i silicijevi dioksidi s dodanim Al, Ti ili Zr u različitim morfološkim oblicima, heteropolikiseline, kiseline adsorbirane i/ili kovaletno vezane na metalne okside; organske sulfonske i/ili organske karboksilne kiseline nanešene na amorfni silicijev dioksid i/ili mezo i mikrostrukturirani silicijev dioksid; polioksimetalati stabilizirani na silicijevom dioksidu i/ili titanijevom dioksidu; Kegginove strukture koje sadrže niobijeve ione; niobijeve okside; ionske tekućine i/ili ugljikove nanocijevi funkcionalizirane s organskim sulfonskim kiselinama i/ili organskim karboksilnim kiselinama.
The process of any one of claims 1-4, wherein the solution of hydrobromic acid in acetic acid comprises less than 0.01% of free bromine. 
Postupak prema patentnom zahtjevu 1, naznačen time, da otopina bromovodične kiseline u octenoj kiselini sadrži manje od 0,1% slobodnog broma, manje od 0,05% slobodnog broma, manje od 0,01% slobodnog broma, manje od 0,001% slobodnog broma ili je bez broma.
The CD3-binding molecule of claim 11, wherein said molecule is capable of immunospecifically binding to CD3 and to a cell surface antigen, receptor or receptor ligand, wherein said cell surface antigen, receptor or receptor ligand is a molecule involved in a T cell-B cell association, wherein said molecule involved in said T cell-B cell association is selected from the group consisting of CD19, CD20, CD22, CD23, CD27, CD32B, CD38, CD40, CD79a, CD79b, CD80, CD86, LFA-I, LFA-3 and CFA-I. 
CD3-vezujuća molekula prema patentnom zahtjevu 11, naznačena time što navedena molekula je sposobna za imunospecifično vezanje za CD3 i za antigen, receptor ili receptor ligand na staničnoj površini, pri čemu navedeni antigen, receptor ili receptor ligand na staničnoj površini je molekula uključena u vezu T stanice - B stanice, pri čemu je navedena molekula uključen u navedenu vezu T stanice - B stanice izabran iz grupe koja se sastoji od CD19, CD20, CD22, CD23, CD27, CD32B, CD38, CD40, CD79a, CD79b, CD$0, CD86, LFA-I, LFA-3 i CFA-I.
treating a hypophosphatemia disorder, wherein said hypophosphatemia disorder is X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, and autosomal dominant hypophosphatemic rickets, or tumor-induced osteromalacia. 
liječenju poremećaja hipofosfatemije, pri čemu navedeni poremećaj hipofosfatemije je X-vezani hipofosfatemični rahitis, autosomni recesivni hipofosfatemični rahitis, i autosomno dominantni hipofosfatemični rahitis ili osteomalacija izazvana tumorom.
Material according to any of the previous claims, comprising two different materials are co-extruded polyolefin materials, in particular two different polypropylene materials, wherein said nano-material is present in at least one of said different materials. 
Materijal prema bilo kojem prethodnom zahtjevu, naznačen time, da sadrži dva različita materijala koji su koekstrudirani poliolefinski materijali, posebno dva različita polipropilen materijala, gdje spomenuti nano-materijal je prisutan u najmanje jednom od spomenutih različitih materijala.
The fusion peptide according to claim 5, wherein the linker sequence has a length of about 1 to 10 amino acids. 
Fuzijski peptid prema patentnom zahtjevu 6, naznačen time da vezivna sekvenca ima duljinu od 1 do 10 aminokiselina.
aryl; and wherein X9, R9 and R10 can form together with the C atoms to which they are attached an aromatic ring 
*aril; i pri čemu R9 i R10 mogu zajedno s atomima ugljika na koje su oni vezani tvoriti aromatski prsten uz iznimku spojeva, gdje istodobno:
The anti-IL-13 antibody of claim 13, wherein said anti-IL-13 antibody comprises a variable light chain region and a variable heavy chain region and wherein the variable light chain region comprises the amino acid sequence set forth in SEQ ID NO:142 and a variable heavy chain region comprises the amino acid sequence set forth in SEQ ID NO:143. 
Antagonističko protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što navedeno protutijelo sadrži VL područje lanca, koje sadrži slijed iznijet u SEQ ID NO: 142, i VH područje lanca, koje sadrži slijed iznijet u SEQ ID NO: 143.
for use in a method of treatment of a condition caused or characterised by excess body weight, e.g. the treatment and/or prevention of obesity, morbid obesity, obesity linked inflammation, obesity linked gallbladder disease, obesity induced sleep apnea, metabolic syndrome, pre-diabetes, insulin resistance, glucose intolerance, type 2 diabetes, type I diabetes, hypertension, atherogenic dyslipidaemia, atherosclerois, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke or microvascular disease. 
(c) uporabu u postupku liječenja stanja uzrokovanih ili karakteriziranih s viškom tjelesne težine, dok je to liječenje i/ili prevencija za sljedeće: pretilost, morbidna pretilost, upala povezana s pretilosti, bolest žučnog mjehura povezana s pretilosti, apneja u spavanju povezana s pretilosti, metabolički sindrom, pred-dijabetes, otpornost na inzulin, netolerancija na glukozu, dijabetes tipa II, dijabetes tipa I, hipertenzija, aterogena dislipidemija, ateroskleroza, arterioskleroza, koronarna srčana bolest, bolest periferne arterije, udar ili mikrovaskularna bolest.
1, 2 and 3; and a light chain comprising CDR-L1, CDR-L2 and CDR-L3 with respectively the amino acid sequences SEQ ID Nos. 
1, 2 i 3; te laki lanac koji sadrži CDR-L1, CDR-L2 i CDR-L3 s aminokiselinskim sekvencijama SEQ ID Nos.
stereoisomers, tautomers, pharmaceutically acceptable salts, and hydrates thereof. 
ili njihovih stereoizomera, tautomera, soli ili hidrata.
The method of item 6, wherein the system includes one or more test scripts, including test commands defined therein which, when executed by the media device under test, cause the media device to issue requests for the playback or other control of media content associated with the test files. 
Postupak prema zahtjevu 6 ili 7, naznačen time da sustav sadrži jednu ili više testnih skripti (340), uključujući definirane testne naredbe koje, kada se izvršavaju putem medijskog uređaja (350) prilikom testiranja, uzrokuju da medijski uređaj izdaje zahtjeve za pristup mediju za nadziranje, npr. za reprodukciju, medijskog sadržaja povezanog s testnim datotekama (332, 334, 336).
Of this embodiment, another embodiment is a method which further comprises the preparation of the compound of formula (7), or a pharmaceutically acceptable salt thereof, wherein a compound of formula (6): 
Postupak u skladu s patentnim zahtjevom 1, koji se dodatno sastoji u dobivanju spoja formule (7), naznačen time što se postupak sastoji u obradi spoja formule (6):
A method according to claim 9, wherein the method is performed for a duration of at least 3 months. 
Uporaba polietilen glikola prema zahtjevu 17, naznačena time, da je razdoblje primjene najmanje 3 mjeseca.
and reporting the number of daily excretions. 
Broj objave europskog patenta:
For the preparation of a sustained release composition a fluidization apparatus of Glatt GPCG1 type was equipped with a bottom spraying Wurster insert, and 500 g of the product fraction were fed into the container. 
Za priređivanje smjesa s produženim otpuštanjem, uređaj za fluidiziranje tipa Glatt GPCGI1 opremljen je Wurster umetkom za donje raspršivanje i u spremnik je stavljeno i 500 g gore navedene frakcije produkta stavljeno je u spremnik.
represents an amino acid residue having a side chain with an -NH2 group, wherein the -NH2 side chain group is functionalized by -C(O)-R5, wherein R5 may be a moiety comprising up to 50 or up to 100 carbon atoms and optionally heteroatoms selected from halogen, N, O, S and/or P, represents an amino acid residue selected from Asp and Glu, 
predstavlja aminokiselinski ostatak koji ima bočni lanac sa skupinom -NH2, pri čemu je -NH2 skupina bočnog lanca funkcionalizirana s -C(O)-R5, pri čemu R5 može biti dio koji sadrži do 50 ili do 100 ugljikovih atoma i proizvoljno heteroatome odabrane od halogena, N, O, S i/ili P, predstavlja aminokiselinski ostatak kojeg se bira od Asp i Glu,
wherein the at least one prediction unit is one of: a block equal in size to the coding unit; and a block among a plurality of blocks generated by dividing at least one of height and width of a coding unit of a current depth, 
kvantizirane koeficijente transformacije za najmanje jednu transformacijsku jedinicu generirane provođenjem inter predviđanja za barem jednu jedinicu predviđanja u jedinici za kodiranje radi generiranja predviđatelja i provođenje transformacije i kvantizacije na temelju predviđatelja i slike;
According to the present invention there is provided a crystalline hydrated form of the Agent having an X-ruy powder diffraction pattern with peaks at 2-theta (2θ) = 4.3. 
Kristalinični hidratizirani oblik prema Zahtjevu 1, naznačen time da difraktogram X-zraka praškastog oblika spoja posjeduje peakove na 2 theta (20) = 4.3.
It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims. A method of measuring the fraction of viable cells in a tissue-engineered product maintained in a cell culture conditioned medium comprising: 
Postupak prema zahtjevu 1, naznačen time da postupak je postupak mjerenja udjela vijabilnih stanica u produktu preinačenog-tkiva održavanom u mediju za kulturu stanica, te pri čemu se postupak sastoji od:
A compound, or a pharmaceutically acceptable salt thereof, selected from: 
Spoj sukladno patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da je odabran od:
The processing method of claims 5 or 6, wherein the random access response comprises the timing deviation information further not used for the mobile station device to perform uplink timing alignment in the uplink synchronous status. 
Postupak obrade prema zahtjevu 5 ili 6, naznačen time da korak odbacivanja nadalje sadrži, u sinkronom statusu uzlazne veze, ne provođenje usklađivanja vremena uzlazne veze na osnovi informacije o odstupanju vremena sadržane u primljenom odgovoru slučajnog pristupa (S02).
The liquefied gas treatment method according to claim 1, wherein, in the ballast condition, the BOG generated in the cargo tank is supplied as fuel to one of the main engine and the sub engine through the compressor line. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 2, naznačen time što se plinovitu komponentu u trećoj struji, dekomprimiranoj u plinsko-tekuće miješano stanje, spaja s prvom strujom otparenog plina, ispuštenog iz spremnika za teret (11).
R2a and R2b are the same or different and independently hydrogen, halogen, trifluoromethyl, cyano or —SO2CH3; 
Ri Ry su isti ili različiti i neovisno su vodik, halogen, trifluormetil, cijano ili -SO>CH;;
The organic phase was separated and filtered through a Whatman 5 µM filter tube, washing the filter cake with methanol (2x1 mL). 
Organsku fazu se odvoji, te pročisti kroz 5 uM cijevni Whatmanov filtar, uz ispiranje filtarskog kolača metanolom (2 X 1 ml).
Please direct entry of the attached “Sequence Listing” in the above-identified patent application. 
Broj europske prijave patenta: Datum podnošenja europske prijave patenta:
The process according to claim 1, wherein the sulphuric acid and the barium salt are added to the aqueous thorium salt solution one after another and in this order, with a stirring, and the stirring is maintained throughout the coprecipitate formation. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahljeva, naznačen time, da se u pod-koraku 1) u vodenu otopinu torijeve soli dodaje sumporna kiselina i barijeva sol, jedan za drugim tim redoslijedom, uz miješanje, a to se miješanje održava cijelo vrijeme nastanka čestica barij - radij.
reacting compound (3) with compound (6) to form compound (7): and 
(b) reagiranje spoja (3) sa spojem (6) čime se dobiva spoj (7):
A pharmaceutical formulation for use in the treatment of respiratory disease according to claim 10 wherein Compound (I) and Compound (II) are presented in a form adapted for simultaneous administration. 
Farmaceutska formulacija namijenjena upotrebi u liječenju bolesti dišnog sustava u skladu s patentnim zahtjevom 10, naznačena time što se Spoj (1) i Spoj (II) daje u obliku prilagođenom za istodobnu primjenu. s
directing the emission field main lobe (206) at the cable (144), and 
- < usmjeravanje glavnog snopa emitiranog polja (206) na kabel (144), 1
Thus, on the bases of these tests it was found that, with the laminated disc according to the invention, one can work almost twice as fast as with a conventional finishing disc. 
Na taj načinje na osnovi ovih testova bilo nađeno, da rad s lemeliranim diskom koji je u skladu s ovim izumom, može biti gotovo dvostruko tako brz kao što je s konvencionalnim diskom.
Evaporation gave 1a as a yellow oil (46 g, 0.238 mmol). 
Otparavanjem se dobije 1a u obliku žutog ulja (46 g, 0,238 mmol).
R10A and R11A are independently an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative; 
A i R11A su neovisno po izboru supstituirana N-vezana aminokiselina ili po izboru supstituirani esterski derivat N-vezane aminokiseline;
A pharmaceutical composition comprising a double-stranded ribonucleic acid (dsRNA) for inhibiting expression of transthyretin (TTR), wherein the dsRNA comprises a sense strand and an antisense strand, wherein the antisense strand is 19, 20, 21, 22, 23, or 24 nucleotides in length and comprises AUGGAAUACUCUUGGUUACNN (SEQ ID NO:450) and the sense strand of the dsRNA is 19, 20, 21, 22, 23, or 24 nucleotides in length, and comprises a region complementary to the antisense strand, wherein the dsRNA comprises at least one chemically modified nucleotide and wherein the pharmaceutical composition has an ED50 in humans of less than 0.03 mg dsRNA/kg. 
Dvolančana ribonukleinska kiselina (dsRNA) za inhibiranje ekspresije transtiretina (TTR), naznačena time da navedena dsRNA sadrži sensni lanac i antisensni lanac, te antisensni lanac sadrži regiju komplementarnu s dijelom mRNA koja kodira transtiretin (TTR), pri čemu je navedena regija komplementarnosti duljine 19 nukleotida, te antisensni lanac sadrži SEQ ID NO:170, i svaki lanac dsRNA je duljine 19, 20, 21, 22, 23, ili 24 nukleotida; ili
In a further preferred embodiment, the hydrophobic charge-induction step is carried out in combination with one or more steps selected from immobilized metal ion affinity chromatography, ion exchange chromatography, hydrophobic interaction chromatography and reverse phase chromatography. 
U drugoj poželjnoj izvedbi, korak koji uključuje hidrofobnu indukciju naboja provodi se u kombinaciji s jednim ili više koraka koji su izabrani iz afinitetne kromatografije s imobiliziranim metalnim ionima, kromatografije izmjene iona, kromatografije hidrofobnih interakcija te kromatogtafija obrnute faze.
wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein each nucleoside of each wing segment comprises a constrained ethyl nucleoside; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine of the modified oligonucleotide is a 5'-methylcytosine. An antisense compound complementary to human STAT3 for use in a method of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject the antisense compound in a first phase and then a second phase, wherein the first phase involves administering a total weekly dose of the compound in the range of about 15-750 mg for the first 1-10 weeks, and the second phase involves administering a total weekly dose in the range of 15-250 mg for at least 1 week after the loading phase. 
Protusmisleni spoj komplementaran s ljudskim STAT3 za uporabu u postupku liječenja B- staničnog limfoma kod ljudskog subjekta kojem je to potrebno, naznačen time što postupak uključuje davanje subjektu protusmislenog spoja u prvoj fazi i zatim u drugoj fazi, pri čemu prva faza uključuje davanje ukupne tjedne doze spoja u rasponu od 100-750 mg (±12%) tijekom prvih 1-10 tjedana, i druga faza uključuje davanje ukupne tjedne doze u rasponu od 100-250 mg (±12%) tijekom barem 1 tjedan nakon prve faze; i pri čemu je protusmisleni spoj jednolančani modificirani oligonukleotid koji se sastoji od 16 povezanih nukleozida koji imaju nukleobaznu sekvencu koja se sastoji od SEQ ID NO: 12, te sadrži:
One such method involves relating incident laser power arriving at the incident surface (Pi) to the laser power transmitted through the material (Pt) i.e. emerging from the opposite surface, in the relationship: EPMATHMARKEREP Where a is the absorption coefficient and L is the thickness of the material. 
Jedan takav postupak uključuje odnos upadne snage lasera koji dolazi na površinu upadanja (Pi) prema snazi lasera koji se prenosi kroz materijal (Pt), to jest koji izlazi na suprotnoj površini, u relaciji: Pt =Pi x exp"" Gdje je a koeficijent apsorpcije, a L je debljina materijala.
A method for modulating ORL-1 receptor function in a cell, comprising contacting a cell capable of expressing the ORL-1 receptor with an effective amount of the compound or a pharmaceutically acceptable derivative of the compound according to any one of claims 1-13, and wherein preferably 
In vitro metoda za moduliranje funkcije ORL-1 receptora u stanicama, koja sadrži dolaženje u kontakt sa stanicom koja može in vitro eksprimirati ORL-1 receptor pomoću učinkovite količine spoja ili farmaceutski prihvatljivog derivata spoja prema bilo kojem zahtjevu od 1 do 19, naznačena time da je farmaceutski prihvatljiv derivat odabran iz skupine: farmaceutski prihvatljivih soli, slovata, radiomarkiranih derivata, stereoizomera, enantiomera, dijastereoizomera, drugih stereoizomerskih oblika, racemičnih smjesa, geometrijskih izomera i/ili tautomera.